<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579031</url>
  </required_header>
  <id_info>
    <org_study_id>288/15</org_study_id>
    <nct_id>NCT02579031</nct_id>
  </id_info>
  <brief_title>A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</brief_title>
  <acronym>BIOSTEMI</acronym>
  <official_title>A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PCI is considered as the reperfusion strategy of choice for patients with acute STEMI. Data
      from RCTs and meta-analyses demonstrate a consistent and strong signal towards a significant
      reduction in MACE among patients with STEMI undergoing primary PCI with newer generation
      stents with enhanced biocompatibility.

      The present trial aims at filling the current gap of evidence by providing randomized data to
      establish the superior clinical outcome with an ultrathin strut third-generation DES with
      biodegradable polymer designed to improve vascular healing in patients with STEMI undergoing
      primary PCI, compared to the current state-of-the art second-generation DES with permanent
      polymer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Primary percutaneous coronary intervention (PCI) is considered nowadays as the reperfusion
      strategy of choice for patients with acute ST-segment elevation myocardial infarction (STEMI,
      owing to a lower risk of myocardial re-infarction and improved short- and long-term survival
      compared to fibrinolysis. However, STEMI is still associated with poorer clinical outcomes
      after PCI, compared to stable CAD, with higher rates of stent thrombosis and an increased
      risk of myocardial re-infarction persisting throughout long-term follow-up. recent data from
      randomized controlled trials and meta-analyses demonstrate a consistent and strong signal
      towards a significant reduction in major adverse cardiac events among patients with STEMI
      undergoing primary PCI with third-generation DESs, compared with both first-generation and
      second-generation DESs with durable polymer. Importantly, this signal suggesting superiority
      of third-generation DESs in patients with STEMI has never been demonstrated with
      second-generation DESs. Third-generation DESs with enhanced biocompatibility may therefore
      have a particular clinical benefit in high-risk subgroups of patients with delayed vascular
      healing but these data warrants confirmation in appropriately designed randomized controlled
      trials.

      Objective

      The purpose of the study is to compare the safety and efficacy of a novel
      biodegradable-polymer sirolimus-eluting stent (Orsiro®) with a durable-polymer
      everolimus-eluting stent (Xience Xpedition or Xience Alpine®) in a superiority trial among
      patients presenting with acute STEMI and undergoing primary PCI.

      Methods

      Eligible patients with acute STEMI presenting within 24 hours of symptom onset will undergo
      primary PCI. At PCI, the randomly allocated stent has to be implanted in the culprit lesion
      of the target vessel.

      Patients will be followed-up with a hospital visit at 12 months. Patients will be followed-up
      for clinical endpoints by telephone at 30 days and 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (Q-wave and non-Q-wave), or clinically driven target lesion revascularization</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically indicated and not clinically indicated target lesion revascularization (TLR)</measure>
    <time_frame>up to 30 days, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically indicated and not clinically indicated target vessel revascularization (TVR)</measure>
    <time_frame>up to 30 days, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with target vessel failure (TVF)</measure>
    <time_frame>up to 30 days, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with cardiac death</measure>
    <time_frame>up to 30 days, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with all-cause death (cardiac and non-cardiac)</measure>
    <time_frame>up to 30 days, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with myocardial infarction (Q-wave and non-Q-wave)</measure>
    <time_frame>up to 30 days, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with definite stent thrombosis</measure>
    <time_frame>up to 30 days, 1 and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1300</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Novel biodegradable-polymer sirolimus-eluting stent Orsiro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Durable-polymer everolimus-eluting stent Xience</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orsiro</intervention_name>
    <description>Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention</description>
    <arm_group_label>Orsiro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience</intervention_name>
    <description>Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention</description>
    <arm_group_label>Xience</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  ST-segment elevation acute myocardial infarction

          -  Primary PCI occurring within 24 hours of symptom onset

          -  Presence of ≥1 acute infarct artery target vessel with one or more coronary artery
             stenoses in a native coronary artery from 2.25 to 4.0 mm in diameter that can be
             covered with one or multiple coronary stents

        Exclusion Criteria

          -  Known allergy to aspirin, Ticagrelor, Prasugrel, Clopidogrel, Sirolimus, Everolimus or
             contrast media

          -  Planned surgery within 6 months of primary PCI, unless dual antiplatelet therapy could
             be maintained throughout the peri-surgical period

          -  Currently participating in another trial before reaching the primary endpoint

          -  Inability to provide informed consent

          -  Non-cardiac comorbid conditions with life expectancy of less than 1 year

          -  Mechanical complication of acute myocardial infarction

          -  Acute myocardial infarction due to stent thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pilgrim, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Cardiology, Bern University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital, Dep. of Cardiology</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG</name>
      <address>
        <city>Genf</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Wallis</name>
      <address>
        <city>Sion</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triemli</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 Jan 4;361(9351):13-20. Review.</citation>
    <PMID>12517460</PMID>
  </results_reference>
  <results_reference>
    <citation>Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A; European Society of Cardiology Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; EACTS Clinical Guidelines Committee, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL; Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery; European Association of Percutaneous Cardiovascular Interventions. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.</citation>
    <PMID>25173601</PMID>
  </results_reference>
  <results_reference>
    <citation>Kukreja N, Onuma Y, Garcia-Garcia H, Daemen J, van Domburg R, Serruys PW. Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation. Circ Cardiovasc Interv. 2008 Oct;1(2):103-10. doi: 10.1161/CIRCINTERVENTIONS.108.787762. Epub 2008 Sep 3.</citation>
    <PMID>20031664</PMID>
  </results_reference>
  <results_reference>
    <citation>Brodie B, Pokharel Y, Fleishman N, Bensimhon A, Kissling G, Hansen C, Milks S, Cooper M, McAlhany C, Stuckey T. Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. JACC Cardiovasc Interv. 2011 Jan;4(1):30-8. doi: 10.1016/j.jcin.2010.11.004.</citation>
    <PMID>21251626</PMID>
  </results_reference>
  <results_reference>
    <citation>Loh JP, Pendyala LK, Kitabata H, Torguson R, Omar A, Minha S, Chen F, Satler LF, Pichard AD, Waksman R. Comparison of outcomes after percutaneous coronary intervention among different coronary subsets (stable and unstable angina pectoris and ST-segment and non-ST-segment myocardial infarction). Am J Cardiol. 2014 Jun 1;113(11):1794-801. doi: 10.1016/j.amjcard.2014.03.007. Epub 2014 Mar 15.</citation>
    <PMID>24837256</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008 Sep 9;118(11):1138-45. doi: 10.1161/CIRCULATIONAHA.107.762047. Epub 2008 Aug 25.</citation>
    <PMID>18725485</PMID>
  </results_reference>
  <results_reference>
    <citation>Iqbal J, Sumaya W, Tatman V, Parviz Y, Morton AC, Grech ED, Campbell S, Storey RF, Gunn J. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention. 2013 May 20;9(1):62-9. doi: 10.4244/EIJV9I1A10.</citation>
    <PMID>23685296</PMID>
  </results_reference>
  <results_reference>
    <citation>Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Parise H, Mehran R, Stone GW. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation. 2010 Sep 14;122(11):1077-84. doi: 10.1161/CIRCULATIONAHA.109.906040. Epub 2010 Aug 30.</citation>
    <PMID>20805433</PMID>
  </results_reference>
  <results_reference>
    <citation>Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. Circ Cardiovasc Interv. 2013 Aug;6(4):378-90. doi: 10.1161/CIRCINTERVENTIONS.113.000415. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Interv. 2013 Dec;6(6):e80.</citation>
    <PMID>23922145</PMID>
  </results_reference>
  <results_reference>
    <citation>Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD, Virmani R. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014 Jan 14;129(2):211-23. doi: 10.1161/CIRCULATIONAHA.113.001790. Epub 2013 Oct 25.</citation>
    <PMID>24163064</PMID>
  </results_reference>
  <results_reference>
    <citation>Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83. Epub 2007 Jul 30.</citation>
    <PMID>17692740</PMID>
  </results_reference>
  <results_reference>
    <citation>Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999 Dec 23;341(26):1949-56.</citation>
    <PMID>10607811</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Stents</keyword>
  <keyword>Drug-Eluting Stents</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

